EM
MCID: ERY003
MIFTS: 58

Erythema Multiforme (EM)

Categories: Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme

MalaCards integrated aliases for Erythema Multiforme:

Name: Erythema Multiforme 12 74 52 36 54 43 15 17 71 32
Erythema Polymorphe, Erythema Multiforme Type 52
Dermatostomatitis, Erythema Multiforme Type 52
Herpes Iris, Erythema Multiforme Type 52
Febrile Mucocutaneous Syndrome 52
Erythema Multiforme Bullosum 52
Stevens-Johnson Syndrome 71
Em 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0050185
KEGG 36 H01695
MeSH 43 D004892
ICD10 32 L51 L51.9
UMLS 71 C0014742 C0038325

Summaries for Erythema Multiforme

KEGG : 36 Erythema multiforme (EM) is an immune-mediated, mucocutaneous condition characterized by "target" lesions. Classically, EM has been separated into 2 subgroups, EM minor and EM major. In EM minor, lesions often present as papules, which might enlarge and eventually form the typical target lesion with erythema surrounding an area of central clearing. The rash in EM minor preferentially affects the limbs, specifically the extensor surfaces, however, it can also be seen throughout the body, excluding mucous membranes. EM major has mucous membrane involvement. The oral mucosa is most commonly affected, initially with edema that progresses to superficial erosions. Other surfaces that might be involved include the anogenital, ocular, and nasal mucosa. Although previously thought to be on a similar continuum of EM, and histologically appearing the same, Stevens-Johnson syndrome (SJS) is increasingly being considered a separate disease process. It is currently believed that EM is a result of an immune reaction to an inciting infectious or pharmacologic antigen. The most common infectious organisms in EM are herpes simplex virus types 1 and 2, as well as Mycoplasma pneumonia. The first line of treatment for EM is removal of the inciting factor when possible. Systemic steroids have been suggested as adjuvant therapy based on their immunosuppressant effects. To date, their use has been limited to EM major, as EM minor is self-limited.

MalaCards based summary : Erythema Multiforme, also known as erythema polymorphe, erythema multiforme type, is related to severe cutaneous adverse reaction and fixed drug eruption. An important gene associated with Erythema Multiforme is DSP (Desmoplakin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Gabapentin and Bezafibrate have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are cellular and digestive/alimentary

Disease Ontology : 12 A skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness.

NIH Rare Diseases : 52 Erythema multiforme (EM) refers to a group of hypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus , suggesting an immunologic process initiated by the virus . In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics . In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome . The most severe of the three is toxic epidermal necrolysis (TEN).

Wikipedia : 74 Erythema multiforme (EM) is a skin condition of unknown cause; it is a type of erythema possibly... more...

Related Diseases for Erythema Multiforme

Diseases related to Erythema Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1028)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 32.9 TNF GZMB GNLY FASLG FAS
2 fixed drug eruption 31.0 IL2 IFNG
3 herpes zoster 30.8 TNF IL2 IFNG
4 pemphigus 30.7 TNF IL6 IL4 DSP
5 syphilis 30.6 TNF IL6 IFNG FAS
6 exanthem 30.5 TNF IL6 IL2 IFNG CXCL8
7 kawasaki disease 30.4 TNF IL6 IL4 IL2
8 dermatitis herpetiformis 30.4 TNF IL5 IL4 CXCL8
9 acute generalized exanthematous pustulosis 30.3 PTGS2 CXCL8
10 cryoglobulinemia 30.2 TNF IL6 IFNG
11 spondylitis 30.2 TNF IL6 IFNG
12 chickenpox 30.2 TNF IL6 IL4 IL2 IFNG
13 alopecia 30.2 TNF IL4 IL2 IFNG DSP
14 chlamydia pneumonia 30.2 TNF IL6 CXCL8
15 purpura 30.1 TNF IL6 IL4 IFNG
16 cytomegalovirus infection 30.1 TNF IL6 FAS CXCL8
17 haemophilus influenzae 30.1 TNF CXCL8
18 typhoid fever 30.0 TNF IL6 IFNG
19 bacterial infectious disease 30.0 TNF IL6 IFNG CXCL8
20 poliomyelitis 30.0 TNF IL4 IFNG ICAM1
21 hepatitis b 29.9 TNF IL6 IFNG CXCL8
22 cytokine deficiency 29.9 IL5 IL13
23 pharyngitis 29.9 TNF PTGS2 IL6 CXCL8
24 soft tissue sarcoma 29.9 TNF IFNG
25 peptic ulcer disease 29.9 TNF PTGS2 CXCL8
26 spinal cord injury 29.8 TNF IL6 CXCL8
27 pulpitis 29.8 TNF IL6 CXCL8
28 chorioretinitis 29.8 TNF IL6 IL2 IFNG
29 adult-onset still's disease 29.8 TNF IL6 CXCL8
30 dysentery 29.8 TNF IL6 CXCL8
31 thymoma 29.7 TNF IL6 IL4 IL2 DSP
32 toxic oil syndrome 29.7 IL5 IL4 IFNG
33 legionellosis 29.7 TNF IL6 CXCL8
34 autoimmune hepatitis 29.7 TNF IL6 IL4 FAS
35 acute graft versus host disease 29.7 TNF IL4 IL2 IFNG FASLG
36 reactive arthritis 29.6 TNF IL6 IFNG CXCL8
37 severe acute respiratory syndrome 29.6 TNF IL6 IL2 IFNG CXCL8
38 measles 29.6 TNF IL6 IL2 IFNG CXCL8
39 urticaria 29.6 TNF PTGS2 IL6 IL5 IL4 IL13
40 irritant dermatitis 29.6 TNF IL6 IL4 CXCL8
41 yellow fever 29.6 IL6 IL5 IL4
42 vaccinia 29.6 TNF IL6 IL2 ICAM1 GZMB
43 alcoholic hepatitis 29.5 TNF IL6 ICAM1 CXCL8
44 influenza 29.5 TNF IL6 IFNG CXCL8
45 endophthalmitis 29.5 TNF IL6 ICAM1 CXCL8
46 acquired immunodeficiency syndrome 29.5 TNF IL6 IL2 IFNG ICAM1
47 graft-versus-host disease 29.5 TNF IL6 IL2 IFNG GZMB FASLG
48 orofacial granulomatosis 29.5 TNF IL4 IFNG CXCR3
49 folliculitis 29.5 TNF IL5 IL4 IFNG GNLY
50 neutropenia 29.5 TNF IL6 IL2 IFNG FASLG CXCL8

Comorbidity relations with Erythema Multiforme via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Erythema Multiforme:



Diseases related to Erythema Multiforme

Symptoms & Phenotypes for Erythema Multiforme

MGI Mouse Phenotypes related to Erythema Multiforme:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CCL17 CXCR3 DSP FAS FASLG ICAM1
2 digestive/alimentary MP:0005381 10.34 DSP FAS FASLG ICAM1 IFNG IL13
3 hematopoietic system MP:0005397 10.34 CCL17 CXCR3 FAS FASLG ICAM1 IFNG
4 immune system MP:0005387 10.31 CCL17 CXCR3 FAS FASLG ICAM1 IFNG
5 homeostasis/metabolism MP:0005376 10.29 CXCR3 FAS FASLG ICAM1 IFNG IL13
6 growth/size/body region MP:0005378 10.28 DSP FAS ICAM1 IFNG IL13 IL2
7 cardiovascular system MP:0005385 10.27 CXCR3 DSP FAS FASLG ICAM1 IFNG
8 endocrine/exocrine gland MP:0005379 10.25 FAS FASLG ICAM1 IFNG IL13 IL2
9 mortality/aging MP:0010768 10.21 CXCR3 DSP FAS FASLG ICAM1 IFNG
10 integument MP:0010771 10.18 DSP FAS FASLG ICAM1 IFNG IL13
11 liver/biliary system MP:0005370 10.11 FAS FASLG IFNG IL2 IL4 IL5
12 neoplasm MP:0002006 10.07 CXCR3 FAS FASLG ICAM1 IFNG IL2
13 nervous system MP:0003631 10.02 DSP FAS FASLG ICAM1 IFNG IL13
14 muscle MP:0005369 10.01 DSP FAS ICAM1 IFNG IL13 IL6
15 reproductive system MP:0005389 9.85 FAS FASLG IFNG IL13 IL2 IL4
16 renal/urinary system MP:0005367 9.8 CXCR3 FAS FASLG IFNG IL4 IL6
17 respiratory system MP:0005388 9.7 CXCR3 FAS FASLG IFNG IL13 IL2
18 vision/eye MP:0005391 9.28 FAS FASLG ICAM1 IFNG IL2 IL4

Drugs & Therapeutics for Erythema Multiforme

Drugs for Erythema Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
7 Molgramostim Investigational Phase 4 99283-10-0
8 Ophthalmic Solutions Phase 4
9 Psychotropic Drugs Phase 4
10 Anticonvulsants Phase 4
11 Analgesics, Opioid Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Analgesics Phase 4
14 Hypolipidemic Agents Phase 4
15 Lipid Regulating Agents Phase 4
16 Antimetabolites Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Anti-Anxiety Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Diuretics, Potassium Sparing Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Neurotransmitter Agents Phase 4
23 Adrenergic Agents Phase 4
24 Adrenergic Antagonists Phase 4
25 Sympatholytics Phase 4
26 Adrenergic beta-Antagonists Phase 4
27
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
28
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
29
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
30
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
31
Etravirine Approved Phase 3 269055-15-4 193962
32
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
33
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
35
tannic acid Approved Phase 2, Phase 3 1401-55-4
36 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
37
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
38
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
39
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
40
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
41
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754
42
Hydrocortisone acetate Approved, Vet_approved Phase 2, Phase 3 50-03-3
43
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
44
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
47
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
48
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
49
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
50
Etanercept Approved, Investigational Phase 3 185243-69-0

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
3 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
4 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
5 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Active, not recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Randomised Evaluation of COVID-19 Therapy Recruiting NCT04381936 Phase 2, Phase 3 Lopinavir-Ritonavir;Corticosteroid;Hydroxychloroquine;Azithromycin;Tocilizumab
16 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
17 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
18 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
19 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
20 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
21 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
22 A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Recruiting NCT02658097 Phase 2 Pembrolizumab
23 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
24 Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers. Terminated NCT01892644 Phase 2 Deferasirox;Deferasirox
25 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
26 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
27 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
28 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
29 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
30 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
31 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
32 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
33 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
34 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
35 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
36 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Unknown status NCT03304366
37 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
38 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
39 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
40 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
41 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
42 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
43 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Completed NCT03445312
44 Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial Completed NCT03044197
45 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
46 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
47 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
48 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
49 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
50 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134

Search NIH Clinical Center for Erythema Multiforme

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Cochrane evidence based reviews: erythema multiforme

Genetic Tests for Erythema Multiforme

Anatomical Context for Erythema Multiforme

The Foundational Model of Anatomy Ontology organs/tissues related to Erythema Multiforme:

19
Skin

MalaCards organs/tissues related to Erythema Multiforme:

40
Skin, Eye, Testes, T Cells, Lung, Liver, Salivary Gland

Publications for Erythema Multiforme

Articles related to Erythema Multiforme:

(show top 50) (show all 5532)
# Title Authors PMID Year
1
Detection of autoantibodies to desmoplakin in a patient with oral erythema multiforme. 61 54
17478387 2007
2
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. 61 54
16872242 2006
3
Internalization via plasmalemmal vesicles: a route for antidesmoplakin autoantibodies into cultured human keratinocytes. 61 54
14705794 2003
4
[Erythema multiforme. A heterogeneous pathologic phenotype]. 54 61
10434539 1999
5
Erythema multiforme associated human autoantibodies against desmoplakin I and II. 54 61
10084323 1999
6
Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. 54 61
9740248 1998
7
Antibodies to desmoplakin in a patient with pemphigus foliaceous. 54 61
9784047 1998
8
Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. 61 54
8618031 1996
9
Erythema-multiforme-like eruption due to topical contactants: expression of adhesion molecules and their ligands and characterization of the infiltrate. 61 54
8565488 1995
10
In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. 61 54
7616001 1995
11
Autoantibodies to desmoplakin I and II in patients with erythema multiforme. 54 61
7807001 1995
12
Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. 54 61
2258627 1990
13
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
14
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
15
Clinical clues predictive of Stevens-Johnson syndrome as the cause of chronic cicatrising conjunctivitis. 61
31630093 2020
16
Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32200005 2020
17
Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. 61
31785388 2020
18
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome. 61
32324952 2020
19
Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31000507 2020
20
Ectopic sebaceous glands of Gibsan in eyelid margin- A novel manifestation in Stevens Johnson Syndrome & proposed nomenclature based on an observational case series. 61
32194257 2020
21
Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 61
31923328 2020
22
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever. 61
32506813 2020
23
Allergic contact dermatitis to benzalkonium chloride with erythema multiforme-like reaction in a child. 61
32112429 2020
24
Adenovirus-induced Erythema Multiforme: Eye and Genital Mucosal Involvement is Specific, Whereas Oral and Cutaneous Involvement is Not. 61
32511743 2020
25
Comment on "Are erythema multiforme and urticaria related to a better outcome of COVID 19?". Eosinophils count in 7 patients with COVID-19 and urticarial rash. 61
32544263 2020
26
Histopathological Study of a Broad Spectrum of Skin Dermatoses in Patients Affected or Highly Suspected of Infection by COVID-19 in the Northern Part of Italy: Analysis of the Many Faces of the Viral-Induced Skin Diseases in Previous and New Reported Cases. 61
32576730 2020
27
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. 61
32002848 2020
28
Mycoplasma Pneumoniae Induced Rash and Mucositis (MIRM): A Longitudinal Perspective and Proposed Management Criteria. 61
32574770 2020
29
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immune cell activation. 61
32561372 2020
30
Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. 61
32151629 2020
31
Differences in treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis at burn centers and non-burn centers. 61
32498082 2020
32
Successful use of rifampin in a patient with Stevens-Johnson syndrome to rifabutin. 61
32169513 2020
33
Stevens-Johnson syndrome triggered by Levetiracetam-Caution for use with Carbamazepine. 61
32540638 2020
34
Stevens-Johnson Syndrome Secondary to Doxycycline Treatment in a Teenage Boy. 61
32574716 2020
35
[Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)]. 61
32253008 2020
36
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. 61
32052409 2020
37
Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32028281 2020
38
A pediatric case of Stevens-Johnson syndrome/toxic epidermal necrolysis with rapid response to intravenous cyclosporine. 61
32509946 2020
39
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. 61
31898979 2020
40
Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. 61
32469468 2020
41
An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. 61
32510242 2020
42
Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. 61
31896765 2020
43
Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32513522 2020
44
Reply to: "The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on 'Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients'". 61
32092373 2020
45
The age of procalcitonin: potential pitfalls in critically ill patients with SJS/TEN. A comment on "Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients". 61
32092376 2020
46
The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case-Control Study. 61
32521061 2020
47
Burn center admissions of patients with autoimmune rheumatic diseases: clinical characteristics and outcomes. 61
32507914 2020
48
General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China. 61
32516456 2020
49
Traditional and advanced therapeutic modalities for wounds in the paediatric population: an evidence-based review. 61
32530778 2020
50
Erythema multiforme induced by topical imiquimod. 61
32395940 2020

Variations for Erythema Multiforme

Expression for Erythema Multiforme

Search GEO for disease gene expression data for Erythema Multiforme.

Pathways for Erythema Multiforme

Pathways related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TNF PTGS2 IL6 IL5 IL4 IL2
2
Show member pathways
13.92 TNF PTGS2 IL6 IL5 IL4 IL2
3
Show member pathways
13.76 TNF PTGS2 IL6 IL5 IL4 IL2
4
Show member pathways
13.63 TNF IL6 IL5 IL4 IL2 IL13
5
Show member pathways
13.53 TNF IL6 IL5 IL4 IL2 IL13
6
Show member pathways
13.48 TNF PTGS2 IL6 IL5 IL4 IL2
7
Show member pathways
13.41 TNF IL6 IL5 IL4 IL2 IL13
8
Show member pathways
13.15 TNF IL6 IL2 IFNG FASLG FAS
9
Show member pathways
13.09 TNF PTGS2 IL6 IL4 IL2 FASLG
10
Show member pathways
13.05 TNF PTGS2 IL6 ICAM1 FASLG FAS
11
Show member pathways
12.97 TNF IL6 IL2 IFNG ICAM1 FASLG
12 12.97 PTGS2 IL6 IL5 IL4 IL2 IL13
13
Show member pathways
12.91 FASLG FAS CXCR3 CXCL8 CCL17
14 12.84 TNF IL6 IFNG FASLG FAS
15
Show member pathways
12.76 TNF IL6 IL5 IL4 IL2 IFNG
16
Show member pathways
12.75 TNF IL6 IL5 IL4 IL2 IL13
17 12.72 TNF PTGS2 IL4 IL2 IFNG GZMB
18
Show member pathways
12.66 TNF PTGS2 IL5 IL4 IL13
19
Show member pathways
12.66 TNF IL4 IL2 IFNG ICAM1 GZMB
20
Show member pathways
12.58 IL6 IL5 IL4 IL2 IL13 IFNG
21
Show member pathways
12.51 TNF PTGS2 IL6 IL4 IL2 IFNG
22
Show member pathways
12.49 TNF IL6 IL2 CXCR3 CXCL8 CCL17
23
Show member pathways
12.43 TNF IL6 IL5 IL4 IL2 IL13
24
Show member pathways
12.42 TNF PTGS2 IL6 IFNG CXCL8
25
Show member pathways
12.42 TNF PTGS2 IL6 IL5 IL4 IL13
26 12.39 TNF IL6 IL2 ICAM1
27 12.39 TNF IL6 FASLG FAS CXCL8
28
Show member pathways
12.35 TNF IL6 IL4 IFNG FASLG FAS
29
Show member pathways
12.34 TNF PTGS2 IL6 IL2 CCL17
30
Show member pathways
12.32 TNF PTGS2 IL4 IFNG
31 12.31 TNF GZMB FASLG FAS
32
Show member pathways
12.29 TNF GZMB FASLG FAS
33
Show member pathways
12.27 TNF IFNG FASLG FAS
34 12.26 TNF PTGS2 IL6 IFNG
35 12.25 TNF IL6 IL13 CXCL8
36 12.18 TNF IL6 IL5 IL4 IL2 IFNG
37
Show member pathways
12.18 TNF IL6 IL5 IL4 IL2 IL13
38
Show member pathways
12.14 IL4 IL2 IFNG GZMB FASLG
39 12.14 TNF PTGS2 IL6 IL4 IL2 IFNG
40 12.13 TNF PTGS2 IL6 ICAM1 FAS
41 12.11 TNF IL6 IL2 CXCL8
42
Show member pathways
12.06 TNF IL6 IL2 IFNG
43 12.06 TNF PTGS2 IL6 IL4 IL13 ICAM1
44 12.05 TNF PTGS2 ICAM1 CXCL8
45 12.04 TNF IL6 IFNG ICAM1 CXCL8
46 12.03 TNF IL6 IFNG CXCL8
47 12.02 TNF IL6 ICAM1 CXCL8
48 12.02 TNF IL6 IL5 IL4
49
Show member pathways
11.98 IL6 IL4 IFNG GZMB
50
Show member pathways
11.9 IL6 ICAM1 CXCL8

GO Terms for Erythema Multiforme

Cellular components related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF IL6 IL5 IL4 IL2 IL13
2 external side of plasma membrane GO:0009897 9.63 TNF IL13 ICAM1 FASLG FAS CXCR3
3 membrane raft GO:0045121 9.56 TNF ICAM1 FASLG FAS
4 extracellular space GO:0005615 9.4 TNF IL6 IL5 IL4 IL2 IL13

Biological processes related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.09 PTGS2 IL6 IL4 IL2 FAS
2 positive regulation of gene expression GO:0010628 10.06 TNF IL6 IL4 IL13 IFNG
3 positive regulation of cell proliferation GO:0008284 10.02 PTGS2 IL6 IL5 IL4 IL2 IFNG
4 positive regulation of apoptotic process GO:0043065 10.01 TNF PTGS2 IL6 FASLG FAS
5 positive regulation of protein phosphorylation GO:0001934 9.94 TNF IL2 IFNG FAS
6 cellular response to lipopolysaccharide GO:0071222 9.94 TNF IL6 ICAM1 CXCL8
7 response to lipopolysaccharide GO:0032496 9.92 PTGS2 IL13 ICAM1 FASLG
8 cellular response to interferon-gamma GO:0071346 9.9 ICAM1 FASLG CCL17
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 IL6 IL5 ICAM1
10 positive regulation of inflammatory response GO:0050729 9.89 TNF IL2 IFNG
11 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 TNF FASLG FAS
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 TNF PTGS2 IL6
13 cellular response to interleukin-1 GO:0071347 9.87 ICAM1 CXCL8 CCL17
14 cellular response to mechanical stimulus GO:0071260 9.87 PTGS2 IL13 FAS
15 inflammatory response GO:0006954 9.86 TNF PTGS2 IL6 IL5 IL13 CXCR3
16 chemokine-mediated signaling pathway GO:0070098 9.85 CXCR3 CXCL8 CCL17
17 apoptotic signaling pathway GO:0097190 9.84 TNF FASLG FAS
18 response to glucocorticoid GO:0051384 9.83 TNF PTGS2 IL6
19 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL4 IL2
20 humoral immune response GO:0006959 9.83 TNF IL6 IFNG
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 TNF PTGS2 IL6 IL13
22 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.78 ICAM1 FASLG FAS
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.77 IL4 IL13 ICAM1
24 extrinsic apoptotic signaling pathway GO:0097191 9.76 TNF IFNG FASLG FAS
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.75 IL4 IL2 FAS
26 positive regulation of JAK-STAT cascade GO:0046427 9.74 TNF IL6 IL5
27 negative regulation of calcium ion transport GO:0051926 9.72 PTGS2 ICAM1
28 macrophage activation GO:0042116 9.72 IL4 IL13
29 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6
30 positive regulation of podosome assembly GO:0071803 9.71 TNF IL5
31 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.71 TNF IL6 ICAM1
32 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 TNF PTGS2 IFNG ICAM1
33 positive regulation of interleukin-10 secretion GO:2001181 9.7 IL4 IL13
34 regulation of neuroinflammatory response GO:0150077 9.7 PTGS2 IL6
35 positive regulation of mast cell degranulation GO:0043306 9.7 IL4 IL13
36 positive regulation of chemokine biosynthetic process GO:0045080 9.7 TNF IL4 IFNG
37 negative regulation of amyloid-beta clearance GO:1900222 9.69 TNF IFNG
38 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL4 IFNG
40 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
41 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL4 IL2
42 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.67 TNF IFNG
43 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL5 IL2
44 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL2 IL13
45 positive regulation of mononuclear cell migration GO:0071677 9.65 TNF IL4
46 cytokine-mediated signaling pathway GO:0019221 9.65 TNF PTGS2 IL6 IL5 IL4 IL2
47 positive regulation of cellular respiration GO:1901857 9.63 IL4 IFNG
48 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
49 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TNF IL6 IL4 IL2 IL13 IFNG
50 positive regulation of fever generation GO:0031622 9.62 TNF PTGS2

Molecular functions related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.06 TNF PTGS2 IL6 IL5 IL4 IL2
2 cytokine activity GO:0005125 9.32 TNF IL6 IL5 IL4 IL2 IL13
3 growth factor activity GO:0008083 9.26 IL6 IL5 IL4 IL2

Sources for Erythema Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....